Sugi Predict

Sugi Predict / Compounds / SCHEMBL342689

SCHEMBL342689

SCHEMBL342689

C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)CC(O)[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HSD17B10 Q99714 10/20 0.71
▸ NR3C1 P04150 5/20 0.71
▸ SERPINA6 P08185 4/20 0.71
▸ LMNA P02545 3/20 0.71
▸ TSHR P16473 3/20 0.71
▸ SHBG P04278 3/20 0.71
▸ CYP3A4 P08684 3/20 0.71
▸ SMN1; SMN2 Q16637 3/20 0.71
▸ ALDH1A1 P00352 2/20 0.71
▸ PMP22 Q01453 2/20 0.71
▸ CYP2D6 P10635 1/20 0.71
▸ KCNA1 Q09470 1/20 0.71
▸ SLC47A1 Q96FL8 1/20 0.71
▸ HIF1A Q16665 5/20 0.65
▸ KMT2A Q03164 4/20 0.65
▸ MEN1 O00255 2/20 0.65
▸ PGR P06401 2/20 0.65
▸ SLC29A1 Q99808 1/20 0.65
▸ TDP1 Q9NUW8 1/20 0.65
▸ CYP2C19 P33261 3/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8217259 1.00 HSD17B10 (0.71) HSD17B10NR3C1SERPINA6LMNATSHR
SCHEMBL4971575 0.90 HSD17B10 (0.71) HSD17B10NR3C1SERPINA6LMNATSHR
SCHEMBL28023466 0.90 HSD17B10 (0.71) HSD17B10NR3C1SERPINA6LMNATSHR
SCHEMBL259724 0.90 HSD17B10 (0.70) HSD17B10NR3C1SERPINA6LMNATSHR
SCHEMBL5082089 0.90 HSD17B10 (0.70) HSD17B10NR3C1SERPINA6LMNATSHR
SCHEMBL28941264 0.89 HSD17B10 (0.69) HSD17B10NR3C1SERPINA6LMNATSHR
SCHEMBL27607895 0.89 HSD17B10 (0.69) HSD17B10NR3C1SERPINA6LMNATSHR
SCHEMBL30483614 0.88 HSD17B10 (0.68) HSD17B10NR3C1SERPINA6LMNATSHR
SCHEMBL21875771 0.86 HSD17B10 (0.66) HSD17B10NR3C1SERPINA6LMNATSHR
SCHEMBL23645479 0.86 HSD17B10 (0.69) HSD17B10NR3C1SERPINA6LMNATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 777 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024199444-A1 HETEROAROMATIC RING COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF 上海翊维康医药有限责任公司 2024-10-03 — — WO claimed
US-20240240157-A1 Structure and Use Thereof CELLFIBER CO., LTD. (JP) 2024-07-18 — — US claimed
WO-2024149239-A1 HETEROAROMATIC CYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF 上海翊维康医药有限责任公司 2024-07-18 — — WO claimed
EP-4372075-A1 STRUCTURE AND USE THEREOF Cellfiber Co., Ltd. (JP) 2024-05-22 — — EP claimed
US-20240156835-A1 USE OF GLUCOCORTICOID RECEPTOR ANTAGONISTS IN COMBINATION WITH GLUCOCORTICOIDS TO TREAT ADRENAL INSUFFICIENCY CORCEPT THERAPEUTICS, INC. (US) 2024-05-16 — — US claimed
US-11890289-B2 Use of glucocorticoid receptor antagonists in combination with glucocorticoids to treat adrenal insufficiency CORCEPT THERAPEUTICS, INC. (US) 2024-02-06 — — US claimed
EP-4233870-A2 ANTI-CANCER EFFECTS OF JAK2 INHIBITORS IN COMBINATION WITH THALIDOMIDE DERIVATIVES AND GLUCOCORTICOIDS Onco Tracker, Inc. (US) 2023-08-30 — — EP claimed
US-20230233579-A1 ANTI-CANCER EFFECTS OF JAK2 INHIBITORS IN COMBINATION WITH THALIDOMIDE DERIVATIVES AND GLUCOCORTICOIDS Oncotracker, Inc. 2023-07-27 — — US claimed
EP-3148545-B1 ANTI-CANCER EFFECTS OF JAK2 INHIBITORS IN COMBINATION WITH THALIDOMIDE DERIVATIVES AND GLUCOCORTICOIDS ONCO TRACKER INC (US) 2023-03-15 — — EP claimed
WO-2023286852-A1 STRUCTURE AND USE THEREOF 株式会社セルファイバ 2023-01-19 — — WO claimed
US-20060057183-A1 Indwelling stent KANEKA CORPORATION (JP) 2006-03-16 — — US claimed
EP-1586346-A1 INDWELLING STENT KANEKA CORPORATION (JP) 2005-10-19 — — EP claimed
WO-2003045353-A1 METHOD FOR THE PREPARATION OF PHARMACEUTICAL NANOSUSPENSIONS USING SUPERSONIC FLUID FLOW JAGOTEC AG (CH) 2003-06-05 — — WO claimed
WO-2002098403-A1 STEROID HORMONE AND NON-STEROIDAL ANTI-INFLAMMATORY DRUG COMBINATIONS FOR INDUCING TUMOR CELL APOPTOSIS GEORGETOWN UNIVERSITY (US) 2002-12-12 — — WO claimed
US-5858410-A Pharmaceutical nanosuspensions for medicament administration as systems with increased saturation solubility and rate of solution MEDAC GESELLSCHAFT FUR KLINISCHE SPEZIALPRAPARATE (DE) 1999-01-12 — — US claimed
EP-0876131-A4 — — 1998-12-02 — — EP claimed
EP-0876131-A1 DRUG DELIVERY COMPOSITIONS FOR IMPROVED STABILITY OF STEROIDS THERATECH, INC. (a Delaware Corporation) (US) 1998-11-11 — — EP claimed
US-5780050-A STORAGE-STABLE PATCH FOR TRANSDERMAL DELIVERY OF 3-KETO-4-EN-CONTAINING STEROID USING A BIOCOMPATABLE ADHESIVE COMPRISING A BLOCK POLYMER OF HYDROXYETHYL ACRYLATE AND N-VINYL-2-PYRROLIDONE; ACID-FREE THERATECH, INC. (US) 1998-07-14 — — US claimed
WO-1997003629-A1 DRUG DELIVERY COMPOSITIONS FOR IMPROVED STABILITY OF STEROIDS THERATECH, INC. (US) 1997-02-06 — — WO claimed
US-4551332-A MIXTURE WITH GLYCERYL STEARATE, DERMATOLOGICAL COATINGS STILLMAN THEODORE 1985-11-05 — — US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240156835-A1 USE OF GLUCOCORTICOID RECEPTOR ANTAGONISTS IN COMBINATION WITH GLUCOCORTICOIDS TO TREAT ADRENAL INSUFFICIENCY NR3C2, MC2R, NR3C1 HSD17B10 289/4885NR3C1 3/4885SERPINA6 20/4885
US-11890289-B2 Use of glucocorticoid receptor antagonists in combination with glucocorticoids to treat adrenal insufficiency NR3C2, MC2R, NR3C1 HSD17B10 289/4885NR3C1 3/4885SERPINA6 20/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.